Literature DB >> 8108142

Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.

A Kieser1, H A Weich, G Brandner, D Marmé, W Kolch.   

Abstract

Many tumor cells produce vascular endothelial growth factor (VEGF), which is thought to be a pivotal mediator of tumor neoangiogenesis. Expression of the VEGF gene can be induced by tumor promoting phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), which activate protein kinase C (PKC). Here we show that in transient transfection assays a mutated form of the murine p53 tumor suppressor gene (ala135-->val) induces expression of VEGF mRNA and potentiates TPA stimulated VEGF mRNA expression. In NIH 3T3 cells which stably overexpress the temperature sensitive p53 (ala135-->val), displaying mutant phenotype at 37 degrees C and wildtype phenotype at 32.5 degrees C, induction of VEGF mRNA and protein by activated PKC is strongly synergistic with mutant, but not wildtype p53. Mutant p53 specifically increases TPA induction of VEGF without affecting the expression of other TPA inducible genes. TPA dependent VEGF expression is also enhanced by human p53 mutated at amino acid 175. Thus, our data link PKC and p53, the gene most frequently altered in human tumors, with the regulation of tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8108142

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  89 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.

Authors:  P Vajkoczy; M D Menger; B Vollmar; L Schilling; P Schmiedek; K P Hirth; A Ullrich; T A Fong
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

4.  Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Authors:  M Branca; C Giorgi; D Santini; L Di Bonito; M Ciotti; A Benedetto; P Paba; S Costa; D Bonifacio; P Di Bonito; L Accardi; C Favalli; K Syrjänen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Stretch-induced VEGF expression in the heart.

Authors:  J Li; T Hampton; J P Morgan; M Simons
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

6.  VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells.

Authors:  T Fujisawa; J Watanabe; Y Kamata; M Hamano; H Hata; H Kuramoto
Journal:  Hum Cell       Date:  2003-03       Impact factor: 4.174

Review 7.  Response of tumour cells to hypoxia: role of p53 and NFkB.

Authors:  J A Royds; S K Dower; E E Qwarnstrom; C E Lewis
Journal:  Mol Pathol       Date:  1998-04

Review 8.  Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction.

Authors:  James W Yockman; Andrew Kastenmeier; Harold M Erickson; Jonathan G Brumbach; Matthew G Whitten; Aida Albanil; Dean Y Li; Sung Wan Kim; David A Bull
Journal:  J Control Release       Date:  2008-07-06       Impact factor: 9.776

9.  CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; T Schmid; E Gunsilius; G Hilbe; E Wöll; C M Kähler
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

10.  Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy.

Authors:  Myung-Ju Ahn; Jung-Hye Choi; Ho-Suk Oh; Young-Yeul Lee; In-Soon Kim; Il-Young Choi; Kang-Hong Lee; Kang-Won Song; Chan-Kum Park
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.